A publicly traded clinical-stage biotech firm based in Houston announced it obtained the exclusive global licensing rights to a proprietary Exosome Engineering Technology (EET) from Carnegie Mellon University.
Coya Therapeutics Inc. (NASDAQ: COYA) said the tech has multiple use cases for indications like neurodegeneration, autoimmune and oncology.
The EET from CMU allows Coya to manipulate and modify exosomes, which are extracellular vesicles that can carry information between cells in the body. Coya said researchers have been trying to use exosomes as a drug-delivery mechanism but technical and scientific limitations that relied on certain cellular-level modifications have prevented the use of exosomes for these purposes until now.
"The science behind the technology is strong and has focused on overcoming the limitations of exosomes," Fred Grossman, president and chief medical officer at Coya, said in a statement. "We believe this technology can shape the future of targeted delivery of desired agents to address multiple conditions."
An option period using the EET proved successful for Coya to use the patented technology in a way that did not require genetic modifications. It has set the company up to expand business development and partnership opportunities as a result, the firm said.
